COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS

肌萎缩侧索硬化症的联合药物选择试验

基本信息

  • 批准号:
    7725029
  • 负责人:
  • 金额:
    $ 0.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-12-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Multiple factors are responsible for disease causation in amyotrophic lateral sclerosis (ALS or Lou Gehrig s disease). Excess free radicals, energy mishandling, excitotoxicity, activation of cell death pathways and inflammation likely all contribute to disease causation and progression in ALS. Past clinical trials may have been negative in part because they tested single agents, usually influencing only one mechanism of cell death. Combinations of agents that affect different and multiple mechanisms of neurodegeneration may be necessary to reach meaningful outcomes in trials of ALS. This trial attempts two novel concepts in ALS: 1) a novel study design aimed at faster screening of medications that are effective; and 2) novel combination of drugs targeting different aspects of disease.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAHSEEN MOZAFFAR其他文献

TAHSEEN MOZAFFAR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAHSEEN MOZAFFAR', 18)}}的其他基金

Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation
NT5c1A 抗体对散发性包涵体肌炎疾病进展、临床表型以及血液和肌肉生物标志物的影响 - 前瞻性评估
  • 批准号:
    10596154
  • 财政年份:
    2021
  • 资助金额:
    $ 0.55万
  • 项目类别:
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation
NT5c1A 抗体对散发性包涵体肌炎疾病进展、临床表型以及血液和肌肉生物标志物的影响 - 前瞻性评估
  • 批准号:
    10381454
  • 财政年份:
    2021
  • 资助金额:
    $ 0.55万
  • 项目类别:
UCI-NEXT, a NeuroNEXT site
UCI-NEXT,NeuroNEXT 网站
  • 批准号:
    10192846
  • 财政年份:
    2018
  • 资助金额:
    $ 0.55万
  • 项目类别:
UCI-NEXT, a NeuroNEXT site
UCI-NEXT,NeuroNEXT 网站
  • 批准号:
    9983184
  • 财政年份:
    2018
  • 资助金额:
    $ 0.55万
  • 项目类别:
UCI-NEXT, a NeuroNEXT site
UCI-NEXT,NeuroNEXT 网站
  • 批准号:
    10407606
  • 财政年份:
    2018
  • 资助金额:
    $ 0.55万
  • 项目类别:
A MULTICENTER STUDY FOR THE VALIDATION OF ALS BIOMARKERS
验证 ALS 生物标志物的多中心研究
  • 批准号:
    8166934
  • 财政年份:
    2009
  • 资助金额:
    $ 0.55万
  • 项目类别:
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY
协议 AALS-001 的开放标签扩展(
  • 批准号:
    7725027
  • 财政年份:
    2007
  • 资助金额:
    $ 0.55万
  • 项目类别:
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC
多中心、III 期、随机、双盲、安慰剂对照诊所
  • 批准号:
    7724999
  • 财政年份:
    2007
  • 资助金额:
    $ 0.55万
  • 项目类别:
A MULTICENTER, DOSE RANGING SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN)
阿莫洛莫尔的多中心、剂量范围安全性和药代动力学研究
  • 批准号:
    7606647
  • 财政年份:
    2006
  • 资助金额:
    $ 0.55万
  • 项目类别:
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS
肌萎缩侧索硬化症的联合药物选择试验
  • 批准号:
    7606663
  • 财政年份:
    2006
  • 资助金额:
    $ 0.55万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 0.55万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了